Best of the year: Advanced breast cancer in 2023

Bibliographic Details
Published in:	Breast
Main Authors:	Ilana Schlam, Mariana Chavez-MacGregor
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Subjects:	Breast cancer Metastatic breast cancer Advanced breast cancer Capivasertib Elacestrant Sacituzumab govitecan
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977624000080

Similar Items

Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes
by: Semir Vranic
Published: (2023-03-01)

Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis
by: Roberta Caputo, et al.
Published: (2024-03-01)

A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors
by: Giuliana Pavone, et al.
Published: (2021-12-01)

Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysis
by: Yaping Zhang, et al.
Published: (2025-06-01)

Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis
by: Yilai Wu, et al.
Published: (2024-04-01)

Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
by: Stefano Testa, et al.
Published: (2023-09-01)

Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer
by: Giuseppe Saltalamacchia, et al.
Published: (2024-02-01)

Effectiveness and Safety of Sacituzumab Govitecan in Real-World Clinical Practice in Patients with Metastatic Triple-Negative and HR+/HER2-Negative Breast Cancer
by: Fernando Lago-Ballester, et al.
Published: (2025-08-01)

UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan
by: Megan H. Wong, et al.
Published: (2024-08-01)

Next generation selective estrogen receptor degraders in postmenopausal women with advanced-stage hormone receptors-positive, HER2-negative breast cancer
by: Baha’ Sharaf, et al.
Published: (2024-05-01)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
by: Jiao Xie, et al.
Published: (2023-06-01)

Sacituzumab Govitecan for Second and Subsequent Line Palliative Treatment of Patients with Triple-Negative Breast Cancer: A Polish Real-World Multicenter Cohort Study
by: Miroslawa Püsküllüoğlu, et al.
Published: (2024-09-01)

Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis
by: George W. Jr. Sledge, et al.
Published: (2025-08-01)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer
by: Yitian Lang, et al.
Published: (2023-04-01)

Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis
by: Maria Inez Dacoregio, et al.
Published: (2025-02-01)

Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy
by: Jae Ho Jeong, et al.
Published: (2022-12-01)

Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions
by: Yujun Tong, et al.
Published: (2024-11-01)

Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer
by: Mita Manna, et al.
Published: (2024-09-01)

Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US payer perspective
by: Wanxian Zeng, et al.
Published: (2023-12-01)

Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany
by: Amelie Wickmann, et al.
Published: (2024-03-01)

Case Report: Personalized treatment in stage IV breast cancer using the patient-derived organoids
by: Wu Ying, et al.
Published: (2025-07-01)

Sacituzumab govitecan response in extensive leptomeningeal carcinomatosis from triple-negative breast cancer: a case report
by: Jesús Yaringaño, et al.
Published: (2024-08-01)

Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report
by: Pierluigi di Mauro, et al.
Published: (2023-02-01)

Comparative pharmacological analysis of fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy: Two recently developed chemotherapies in the crucial battle against breast cancer
by: Amjad Z. Alrosan, et al.
Published: (2025-06-01)

Management of HER2-Low Metastatic Breast Cancer: A Comprehensive Statement by an Expert Group from the Middle East and Africa Region
by: Shaheenah Dawood, et al.
Published: (2025-10-01)

Cost-effectiveness of sacituzumab govitecan for hormone receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer based on the EVER-132-002 trial in China
by: Shixian Liu, et al.
Published: (2025-03-01)

Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles
by: Mary Anne Fenton, et al.
Published: (2023-11-01)

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
by: Mythili Shastry, et al.
Published: (2022-12-01)

Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine
by: Saif Khan, et al.
Published: (2024-12-01)

Partial Response Achieved in a Case of Metastatic Triple-Negative Breast Cancer Based on the Patient-Derived Tumor Organoids
by: Liu Y, et al.
Published: (2025-07-01)

Multimodal evaluation of cerebrospinal fluid from breast cancer leptomeningeal metastases using circulating tumor cell detection, single-cell sequencing, and proteomics
by: Elnaz Rahbarlayegh, et al.
Published: (2025-07-01)

Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer
by: Hope S. Rugo, et al.
Published: (2025-03-01)

Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study
by: E. Fountzilas, et al.
Published: (2025-03-01)

Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
by: Demin Shi, et al.
Published: (2023-05-01)

Advanced Breast Cancer: Case Reports and Statistical Analysis
by: Sopotenski S., et al.
Published: (2024-12-01)

Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back
by: Valentina Rossi, et al.
Published: (2024-08-01)

Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis
by: Geneva Guarin, et al.
Published: (2024-11-01)

Elacestrant in hormone receptor-positive metastatic breast cancer: a post-hoc analysis
by: Azza Sarfraz, et al.
Published: (2025-02-01)

6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
by: Fatima Cardoso, et al.
Published: (2024-08-01)

Current perspectives and global trends of nanotechnology in advanced breast cancer: a bibliometric and visualized analysis
by: Hanwen Huang, et al.
Published: (2025-08-01)